Incretin Agonists — GLP-1 and Amylin Research Compounds

These compounds act on the incretin and amylin receptor systems. They are grouped below by receptor coverage — which receptors each one binds — not by any order of use. Portal to Wellness does not publish protocols, combinations or quantities.

---

GIP and GLP-1 dual agonists

Tirzepatide binds both the GIP and the GLP-1 receptor. Much of the published literature on dual incretin agonism is built on this compound.

GLP-1 receptor agonists

Semaglutide binds the GLP-1 receptor alone, and is the reference compound for single-receptor incretin agonism in the published literature. It is supplied in two vial sizes; vial size is a quantity of material, not a stage in a research programme.

---

Triple receptor agonists

---

Additional compounds in this class

Cagrilintide, supplied on its own as an amylin analogue, and 5-Amino-1MQ, which inhibits nicotinamide N-methyltransferase (NNMT) and is not an incretin agonist.

---

The Metabolic Research Kit page carries compound-level write-ups and mechanism detail for this class.

---

📚 From the Research Library: GLP-1 and metabolic research

Go deeper with our Research Library — published literature summaries behind these compounds.

• SURMOUNT-MMO Trial Explained
• Stopping a GLP-1: What the Research Shows About Regain
• Injectable vs. Oral GLP-1: What Researchers Need to Know